Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 20;20(11):e287.
doi: 10.2196/jmir.9825.

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study

Chee Kin Lam  1   2 , Kara McGinnis Pilote  1   2 , Ashraful Haque  2 , Joseph Burzynski  2 , Christine Chuck  2 , Michelle Macaraig  2
Affiliations

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study

Chee Kin Lam et al. J Med Internet Res. .

Abstract

Background: Since January 2013, the New York City (NYC) Health Department Tuberculosis (TB) Program has offered persons diagnosed with latent TB infection (LTBI) the 3-month, once-weekly isoniazid and rifapentine (3HP) treatment regimen. Patients on this treatment are monitored in-person under directly observed therapy (DOT). To address patient and provider barriers to in-person DOT, we piloted the use of a videoconferencing software app to remotely conduct synchronous DOT (video directly observed therapy; VDOT) for patients on 3HP.

Objective: The objective of our study was to evaluate the implementation of VDOT for patients on 3HP and to assess whether treatment completion for these patients increased when they were monitored using VDOT compared with that using the standard in-person DOT.

Methods: Between February and October 2015, patients diagnosed with LTBI at any of the four NYC Health Department TB clinics who met eligibility criteria for treatment with 3HP under VDOT (V3HP) were followed until 16 weeks after treatment initiation, with treatment completion defined as ingestion of 11 doses within 16 weeks. Treatment completion of patients on V3HP was compared with that of patients on 3HP under clinic-based, in-person DOT who were part of a prior study in 2013. Furthermore, outcomes of video sessions with V3HP patients were collected and analyzed.

Results: During the study period, 70% (50/71) of eligible patients were placed on V3HP. Treatment completion among V3HP patients was 88% (44/50) compared with 64.9% (196/302) among 3HP patients on clinic DOT (P<.001). A total of 360 video sessions were conducted for V3HP patients with a median of 8 (range: 1-11) sessions per patient and a median time of 4 (range: 1-59) minutes per session. Adherence issues (eg, >15 minutes late) during video sessions occurred 104 times. No major side effects were reported by V3HP patients.

Conclusions: The NYC TB program observed higher treatment completion with VDOT than that previously seen with clinic DOT among patients on 3HP. Expanding the use of VDOT may improve treatment completion and corresponding outcomes for patients with LTBI.

Keywords: computer-assisted therapy; directly observed therapy; mobile phone; telemedicine; videoconferencing.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Outcomes of patients on 3-month, once-weekly treatment with isoniazid and rifapentine referred for video directly observed therapy (DOT; V3HP). MD: medical doctor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi L, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC. Digital health for the End TB Strategy: developing priority products and making them work. Eur Respir J. 2016 Jul;48(1):29–45. doi: 10.1183/13993003.00424-2016. http://erj.ersjournals.com/cgi/pmidlookup?view=long&pmid=27230443 13993003.00424-2016 - DOI - PMC - PubMed
    1. Macaraig M, Lobato MN, McGinnis Pilote K, Wegener D. A National Survey on the Use of Electronic Directly Observed Therapy for Treatment of Tuberculosis. J Public Health Manag Pract. 2017 Jul 07;24(6):567–570. doi: 10.1097/PHH.0000000000000627. - DOI - PubMed
    1. Holzschuh EL, Province S, Johnson K, Walls C, Shemwell C, Martin G, Showalter A, Dunlay J, Conyers A, Griffin P, Tausz N. Use of Video Directly Observed Therapy for Treatment of Latent Tuberculosis Infection - Johnson County, Kansas, 2015. MMWR Morb Mortal Wkly Rep. 2017 Apr 14;66(14):387–389. doi: 10.15585/mmwr.mm6614a3. doi: 10.15585/mmwr.mm6614a3. - DOI - DOI - PMC - PubMed
    1. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016 Oct;13(10):e1002152. doi: 10.1371/journal.pmed.1002152. http://dx.plos.org/10.1371/journal.pmed.1002152 PMEDICINE-D-16-01092 - DOI - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention US Department of Health and Human Services. Division of Tuberculosis Elimination Strategic Plan 2016-2020 https://www.cdc.gov/tb/about/strategicplan.htm .

MeSH terms